[Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma].

View at publisher Summarise with VIRAT
Authors: Ying Yao, Xiaolan Shi, Pan-Feng Wang, Yun Xu, Shuang Yan, Jiajia Meng, Yu-Xin Jiang, Peng Wang, Jing Wang, Xiao Ma, Cheng-Cheng Fu, De-Pei Wu
+1 more Ling-Zhi Yan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVE: To evaluate the feasibility of in-class transition(iCT) first-line bortezomib intolerance to carfilzomib in the treatment of patients with multiple myeloma(MM). METHODS: It was retrospectively collected that the clinical data of MM patients who transitioned to carfilzomib due to intolerance, such as ≥grade 1 painful peripheral neuropathy (PN), during the treatment with first-line bortezomib-based triple regimens in the First Affiliated Hospital of Soochow University and Soochow Hopes Hematology Hospital from March 2023 to January 2025, and their safety and efficacy were analyzed. RESULTS: =0.026). CONCLUSION: The transition of first-line bortezomib intolerance to carfilzomib can significantly improve symptoms such as PN and deepen remission.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Chronic Lymphocytic Leukemia Research Bone health and treatments

Publication details

Journal / source
PubMed
Volume
34
Issue
1
Pages
115–121
Publication date
1 February 2026
Language
ZH